Injection of drug residue as a potential risk factor for HCV acquisition among Montréal young injection drug users

Drug and Alcohol Dependence

Volumn 126, Issue 1-2, 2012, Pages 246-250

  Roy, Élise ^a,b   Arruda, Nelson ^c   Leclerc, Pascale ^b   Haley, Nancy ^b,d   Bruneau, Julie ^d,e   Boivin, Jean François ^f  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b Gouvernement du Quebec   (Canada)

^c Independent Investigator and Consultant   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Drug injection practices; Drug residue injection; Hepatitis C virus; Injection drug use; Prospective cohort study

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SEROCONVERSION; SOCIAL BEHAVIOR; VIRUS TRANSMISSION;

ADOLESCENT; AGE FACTORS; COHORT STUDIES; DATABASES, FACTUAL; DEMOGRAPHY; DRUG RESIDUES; FEMALE; HEPACIVIRUS; HEPATITIS C; HOMELESS YOUTH; HUMANS; MALE; NEEDLE SHARING; PROPORTIONAL HAZARDS MODELS; QUEBEC; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 84867893346     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.05.018     Document Type: Article

References (48)

1. Bourgois P. The moral economies of homeless heroin addicts: confronting ethnography. HIV risk, and everyday violence in San Francisco shooting encampments. Subst. Use Misuse 1998, 33:2323-2351.
2. Bourgois P., Schonberg J. Righteous Dopefiend 2009, University of California Press, Berkeley, CA.
3. Ciccarone D., Bourgois P. Explaining the geographical variation of HIV among injection drug users in the United States. Subst. Use Misuse 2003, 38:2049-2063.
4. Colón H.M., Finlinson H.A., Robles R.R., Deren S., Andía J., Kang S.Y., Oliver-Vélez D. Joint drug purchases and drug preparation risk behaviors among Puerto Rican injection drug users. AIDS Behav. 2001, 5:85-96.
5. Crofts N., Stewart T., Hearne P., Ping X.Y., Breschkin A., Locarnini S. Spread of bloodborne viruses among Australian prison entrants. Br. Med. J. 1995, 310:285-288.
6. De P., Roy é., Boivin J.-F., Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic review and methodological review. J. Viral Hepat. 2008, 15:279-292.
7. Des Jarlais D.C., Diaz T., Perlis T., Vlahov D., Maslow C., Latka M., Rockwell R., Edwards V., Friedman S.F., Monterroso E.R., Williams I., Garfein R.S. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among youth injecting drug users in New York City. Am. J. Epidemiol. 2003, 157:467-471.
8. Doerrbecker J., Friesland M., Ciesek S., Erichsen T.J., Mateu-Gelabert P., Steinmann J., Steinmann J., Pietschmann T., Steinmann E. Inactivation and survival of hepatitis C virus on inanimate surfaces. J. Infect. Dis. 2011, 204:1830-1838.
9. Evans J.L., Hahn J.A., Lum P.J., Stein E.S., Page K. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug Alcohol Depend. 2009, 101:152-157.
10. Fischer B., Rehm J., Patra J., Firestone Cruz M. Changes in illicit opioid use across Canada. CMAJ 2006, 175:1385-1387.
11. Garfein R.S., Doherty M.C., Monterroso E.R., Thomas D.L., Nelson K.E., Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J. Acquir. Immune Defic. Syndr. 1998, 18:S11-S19.
12. Grebely J., Dore G.J. Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J. Infect. Dis. 2011, 203:571-574.
13. Hagan H., McGough J.P., Thiede H., Weiss N.S., Hopkins S., Alexander E.R. Syringe exchange and risk of infection with hepatitis B and C viruses. Am. J. Epidemiol. 1999, 149:203-213.
14. Hagan H., Pouget E.R., Williams I.T., Garfein R.L., Strathdee S.A., Hudson S.M., Latka M.H., Ouellet L.J. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J. Infect. Dis. 2010, 201:378-385.
15. Hagan H., Thiede H., Weiss N.S., Hopkins S.G., Duchin J.S., Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am. J. Public Health 2001, 91:42-46.
16. Hahn J.A., Page-Shafer K., Lum P.J., Bourgois P., Stein E., Evans J.L., Busch M.P., Tobler L.H., Phelps B., Moss A.R. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J. Infect. Dis. 2002, 186:1558-1564.
17. Haley N., Roy é., Leclerc P., Boudreau J.-F., Boivin J.-F. HIV risk profile of male street youth involved in survival sex. Sex. Transm. Inf. 2004, 80:526-530.
18. Hosmer D.W., Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data 1999, John Wiley, New York, NY.
19. INCB (International Narcotics Control Board) Report of the International Narcotics Control Board for 2010 2011, United Nations: International Narcotics Control Board, New York, NY.
20. Institut national de santé publique du Québec, (INSPQ) Surveillance des maladies infectieuses chez les utilisateurs de drogue par injection. épidémiologie du VIH de 1995 à 2009. épidémiologie du VHC de 2003 à 2009 2011, http://www.inspq.qc.ca/pdf/publications/1308_SurvMalInfecUDI_VIH1995-2009VHC2003-2009.pdf (retrieved 30.04.12).
21. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2009, NIH Publication no. 10-7583. 2010, National Institute on Drug Abuse, Bethesda, MD.
22. Judd A., Hutchinson S., Wadd S., Hickman M., Taylor A., Parry J.V., Cameron S., Rhodes T., Ahmed S., Fox R., Renton A., Stimson G.V., Goldberg D. Prevalence of, and risks for, hepatits C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J. Viral Hepat. 2005, 12:655-662.
23. Koester S., Glanz J., Barón A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005, 9:27-39.
24. Leclerc P., Roy é., Morissette C., Alary M., Parent R. Extent and correlates of injection of prescription opioids for non-medical purposes in the SurvUDI network. Can. J. Infect. Dis. Med. Microbiol. 2011, 22:80B.
25. Lucidarme D., Bruandet A., Ilef D., Harbonnier J., Jacob C., Decoster A., Delamare C., Cyran C., van Hoenacker A.F., Frémaux D., Josse P., Emmanuelli J., Le Strat Y., Desenclos J.C., Filoche B. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol. Infect. 2004, 132:699-708.
26. Maher L., Jalaludin B., Chant K.G., Jayasuriya R., Sladden T., Kaldor J.M., Sargent P.L. Incidence and risk factors for hepatitis C seroconversion in injection drug use in Australia. Addiction 2006, 101:1449-1508.
27. Maher L., Li J., Jalaludin B., Chant K.G., Kaldor J.M. High hepatitis C incidence in new injecting drug users: a policy failure?. Aust. N. Z. J. Public Health 2007, 31:30-35.
28. Miller C.L., Johnston C., Spittal P.M., Li K., Laliberté N., Montaner J.S.G., Schechter M.T. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002, 36:737-742.
29. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583.
30. Painstill E., He H., Peters C., Lindenbach B.D., Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J. Infect. Dis. 2010, 202:984-990.
31. Patrick D.M., Tyndall M.W., Cornelisse P.G.A., Li K., Sherlock C.H., Rekart M.L., Strathdee S.A., Currie S.L., Schechter M.T., O'Shaughnessy M.V. Incidence of hepatits C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001, 165:889-895.
32. PHAC (Public Health Agency of Canada) I-Track: Enhanced Surveillance of Risk Behaviours Among People Who Inject Drugs. Phase I Report, August 2006 2006, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, Ottawa, Canada.
33. PHAC (Public Health Agency of Canada), 2009. Epidemiology of Acute Hepatitis C Infection in Canada. Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS), Ottawa, Canada.
34. Power R., Jones S., Kearns G., Ward J. An ethnography of risk management amongst illicit drug injectors and its implications for the development of community-based interventions. Sociol. Health Illn. 1996, 18:86-106.
35. Rothman K.J., Greenland S., Lash T.L. Validity in epidemiologic studies. Modern Epidemiology 2008, 128-147. Lippincott Williams & Wilkins, Philadelphia, PA. 3rd edition. K.J. Rothman, S. Greenland, T.L. Lash (Eds.).
36. Roy é., Alary M., Morissette C., Leclerc P., Boudreau J.-F., Parent R., Rochefort J., Claessens C. High HCV prevalence and incidence among Canadian IDUs. Int. J. STD AIDS 2007, 18:23-27. SurvUDI Working Group.
37. Roy é., Arruda N., Bourgois P. The growing popularity of prescription opioid injection in downtown Montréal: new challenges for harm reduction. Subst. Use Misuse 2011, 46:1142-1150.
38. Roy é., Arruda N., Vaillancourt E., Boivin J.-F., Morissette C., Leclerc P., Alary M., Bourgois P. Drug use patterns in the presence of crack in downtown Montreal. Drug Alcohol Rev. 2012, 31:72-80.
39. Roy E., Boudreau J.-F., Boivin J.-F. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009, 102:158-161.
40. SAMHSA (Substance Abuse and Mental Health Services Administration), 2009. Results from the 2008 National Survey on Drug Use and Health: National Findings. Office of Applied Studies. NSDUH Series H-36, HHS Publication No. SMA 09-4434, Rockville, MD.
41. SAMHSA (Substance Abuse and Mental Health Services Administration), 2010. Results from the 2009 National Survey on Drug Use and Health: Volume I. Sumary of National Findings. Office of Applied Studies. NSDUH Series H-38, HHS Publication No. SMA 10-4856, Rockville, MD.
42. Steensma C., Boivin J.-F., Blais L., Roy é. Cessation of injecting drug use among street-based youth. J. Urban Health 2005, 82:622-637.
43. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., Monterroso E.R., Garfein R.S. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am. J. Epidemiol. 2002, 155:645-653.
44. Thorpe L.E., Ouellet L.J., Levy J.R., Williams I.T., Monterroso E.R. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-2000. J. Infect. Dis. 2000, 182:1588-1594.
45. Tyndall M., Currie S., Spittal P., Li K., Wood E., O'Shaughnessy M.V., Schechter M.T. Intensive cocaine injection use as the primary risk factor in the vancouver HIV-1 epidemic. AIDS 2003, 17:887-893.
46. van Beek I., Dwyer R., Dore G.J., Luo K., Kaldor J.M. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. Br. Med. J. 1998, 137:433-437.
47. van den Berg C.H., Smit C., Bakker M., Geskus R.B., Berkhout B., Jurrians S., Coutinho R.A., Wolthers K.C., Prins M. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur. J. Epidemiol. 2007, 22:183-193.
48. Vlahov D., Fuller C.M., Ompad D.C., Galea S., Des Jarlais D.C. Updating the infection risk reduction hierarchy: preventing transition into injection. J. Urban Health 2004, 81:14-19.